COPENHAGEN, Denmark, Feb. 17, 2026 /PRNewswire/ — Curasight A/S (CPH: CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targetedCOPENHAGEN, Denmark, Feb. 17, 2026 /PRNewswire/ — Curasight A/S (CPH: CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targeted

Curasight to present at TD Cowen’s 46th Annual Health Care Conference in Boston

2026/02/17 15:15
2 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

COPENHAGEN, Denmark, Feb. 17, 2026 /PRNewswire/ — Curasight A/S (CPH: CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targeted radioligand platform therapies across multiple aggressive solid tumors, will present recent company progress including the ongoing Phase 1 clinical trial uTREAT® in glioblastoma, at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3rd, 2026, at 11:50 a.m. Eastern Time / 5:50 p.m. CET in Boston. 

A live audio webcast will be broadcast over the internet simultaneously and will be available in the investor section on Curasight.com approximately 48 hours after the webcast.

During the conference, Curasight management will also hold 1:1 meetings with investors and other industry stakeholders.

The TD Cowen conference is a major investor conference where public and private healthcare companies meet with institutional investors, and large pharma via scheduled 1×1 meetings and presentations combined with fireside chats and innovative panel discussions.

About Curasight A/S

Curasight is advancing uTREAT®, a clinical-stage, first-in-class uPAR-targeted radioligand therapy (RLT) designed to treat solid tumors. uTREAT® targets uPAR, a key driver of tumor invasion, angiogenesis, and metastasis, which is expressed in more than 85% of solid tumors.

The company’s theranostic platform also includes uTRACE®, a uPAR-PET imaging agent built on the same proprietary ligand as uTREAT®. uTRACE® supports patient selection and confirms tumor targeting and has been evaluated in more than 450 patients across nine Phase II trials in eight solid tumor indications.

The uPAR platform is based on more than a decade of research at the Copenhagen University Hospital and the University of Copenhagen.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO
E-mail: uk@curasight.com
www.curasight.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/curasight/r/curasight-to-present-at-td-cowen-s-46th-annual-health-care-conference-in-boston,c4308454

The following files are available for download:

https://mb.cision.com/Main/19744/4308454/3937544.pdf

260217 Curasight Press release – TDCowen

Cision View original content:https://www.prnewswire.com/news-releases/curasight-to-present-at-td-cowens-46th-annual-health-care-conference-in-boston-302689307.html

SOURCE Curasight

Market Opportunity
Cypherium Logo
Cypherium Price(CPH)
$0.004384
$0.004384$0.004384
-0.04%
USD
Cypherium (CPH) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

UK and US Seal $42 Billion Tech Pact Driving AI and Energy Future

UK and US Seal $42 Billion Tech Pact Driving AI and Energy Future

The post UK and US Seal $42 Billion Tech Pact Driving AI and Energy Future appeared on BitcoinEthereumNews.com. Key Highlights Microsoft and Google pledge billions as part of UK US tech partnership Nvidia to deploy 120,000 GPUs with British firm Nscale in Project Stargate Deal positions UK as an innovation hub rivaling global tech powers UK and US Seal $42 Billion Tech Pact Driving AI and Energy Future The UK and the US have signed a “Technological Prosperity Agreement” that paves the way for joint projects in artificial intelligence, quantum computing, and nuclear energy, according to Reuters. Donald Trump and King Charles review the guard of honour at Windsor Castle, 17 September 2025. Image: Kirsty Wigglesworth/Reuters The agreement was unveiled ahead of U.S. President Donald Trump’s second state visit to the UK, marking a historic moment in transatlantic technology cooperation. Billions Flow Into the UK Tech Sector As part of the deal, major American corporations pledged to invest $42 billion in the UK. Microsoft leads with a $30 billion investment to expand cloud and AI infrastructure, including the construction of a new supercomputer in Loughton. Nvidia will deploy 120,000 GPUs, including up to 60,000 Grace Blackwell Ultra chips—in partnership with the British company Nscale as part of Project Stargate. Google is contributing $6.8 billion to build a data center in Waltham Cross and expand DeepMind research. Other companies are joining as well. CoreWeave announced a $3.4 billion investment in data centers, while Salesforce, Scale AI, BlackRock, Oracle, and AWS confirmed additional investments ranging from hundreds of millions to several billion dollars. UK Positions Itself as a Global Innovation Hub British Prime Minister Keir Starmer said the deal could impact millions of lives across the Atlantic. He stressed that the UK aims to position itself as an investment hub with lighter regulations than the European Union. Nvidia spokesman David Hogan noted the significance of the agreement, saying it would…
Share
BitcoinEthereumNews2025/09/18 02:22
Academic Publishing and Fairness: A Game-Theoretic Model of Peer-Review Bias

Academic Publishing and Fairness: A Game-Theoretic Model of Peer-Review Bias

Exploring how biases in the peer-review system impact researchers' choices, showing how principles of fairness relate to the production of scientific knowledge based on topic importance and hardness.
Share
Hackernoon2025/09/17 23:15
BlockchainFX or Based Eggman $GGs Presale: Which 2025 Crypto Presale Is Traders’ Top Pick?

BlockchainFX or Based Eggman $GGs Presale: Which 2025 Crypto Presale Is Traders’ Top Pick?

Traders compare Blockchain FX and Based Eggman ($GGs) as token presales compete for attention. Explore which presale crypto stands out in the 2025 crypto presale list and attracts whale capital.
Share
Blockchainreporter2025/09/18 00:30